Zoetis completes acquisition of VitalRADS
ZoetisAcquirer
VitalRADSTarget
Zoetis announced on August 13, 2026 that it completed the acquisition of VitalRADS, a veterinary teleradiology SaaS platform, with the purchase price undisclosed. The deal adds imaging‑interpretation capabilities to Zoetis’ diagnostics portfolio and creates an end‑to‑end virtual reference lab for companion‑animal care.
Zoetis completed its acquisition of VitalRADS, a veterinary teleradiology SaaS platform, on Aug. 13, 2026, with the transaction value not disclosed. The integration was disclosed during Zoetis’ Q2 2026 earnings call, where management highlighted the move as a step toward an end‑to‑end virtual reference laboratory for companion‑animal diagnostics.
Deal Terms
The acquisition was structured as a cash purchase, though the exact amount was not revealed. VitalRADS brings a cloud‑based workflow that enables remote interpretation of radiology images by board‑certified veterinary radiologists. Zoetis will absorb the platform into its Diagnostics segment, which reported $118 million in revenue for the quarter, up 12% year over year. By adding imaging services, Zoetis aims to deepen its SaaS‑based revenue streams and improve net revenue retention across its diagnostic offerings.
Strategic Rationale
Zoetis’ Diagnostics business has been a growth engine, driven by Vetscan hardware and associated software services. However, the companion‑animal market is under pressure from declining clinic visits and price‑sensitive pet owners. Expanding into teleradiology allows Zoetis to capture higher‑margin, subscription‑based revenue and to cross‑sell imaging interpretation to existing Vetscan users. The move also positions Zoetis against pure‑play veterinary SaaS competitors that already offer integrated imaging solutions.
Integration Outlook
Zoetis plans to roll VitalRADS’ platform into its existing cloud infrastructure over the next 12‑18 months. The combined offering will enable veterinarians to upload radiographs directly from Vetscan devices, receive AI‑assisted triage, and obtain specialist reads within hours. Management expects the expanded service to boost diagnostic‑related expansion revenue and to improve overall gross margin, which currently sits at 72.9%.
The acquisition underscores Zoetis’ broader strategy of building a comprehensive, data‑driven suite of digital tools for animal health, a trend that mirrors larger health‑tech SaaS playbooks in human medicine.
Why It Matters
For Zoetis, the VitalRADS acquisition closes a functional gap in its diagnostics portfolio, giving the company direct control over image interpretation—a service that previously required third‑party partnerships. This vertical integration should enhance cross‑sell opportunities to existing Vetscan customers and improve net revenue retention by bundling hardware, software, and specialist reads into a single subscription. Competitors such as IDEXX and VCA, which already offer integrated imaging solutions, will now face a more robust Zoetis offering that leverages the company’s scale and global distribution network.
VitalRADS gains immediate access to Zoetis’ extensive sales force and international footprint, accelerating its go‑to‑market reach beyond the niche U.S. market where it currently operates. The deal also provides VitalRADS with capital to invest in AI‑driven image analysis, potentially raising the bar for diagnostic accuracy and speed. Direct rivals in the veterinary teleradiology space will need to differentiate on specialty expertise or pricing to retain market share.
Key Points
- Zoetis completed the acquisition of veterinary teleradiology SaaS platform VitalRADS on Aug. 13, 2026; deal value was undisclosed.
- The acquisition expands Zoetis’ Diagnostics segment, which grew 12% YoY to $118 million in Q2 2026.
- VitalRADS adds remote imaging‑interpretation capabilities, enabling an end‑to‑end virtual reference lab for companion‑animal care.
- Zoetis aims to improve net revenue retention and gross margin by bundling hardware, software, and specialist reads into a single subscription offering.
- The deal positions Zoetis against integrated diagnostics competitors such as IDEXX and VCA.
Analysis
While the purchase price was not disclosed, analysts can infer a valuation based on typical SaaS multiples for vertical health‑tech platforms—often ranging from 8‑12 × ARR. Assuming VitalRADS generates roughly $15 million in annual recurring revenue, the implied multiple would sit near the low end of the range, suggesting a disciplined price that aligns with Zoetis’ cash‑rich balance sheet. The transaction reflects a broader trend of large animal‑health incumbents acquiring niche SaaS providers to build end‑to‑end digital ecosystems, mirroring moves in human health‑tech where diagnostic data, AI, and remote specialist services are converging. For investors, the deal signals that capital will continue to flow into specialized SaaS verticals that can be integrated into larger product suites, offering higher gross margins and sticky revenue. Operators should note the importance of building modular, API‑first platforms that can be readily absorbed by industry giants, as the path to scale increasingly runs through strategic acquisition rather than organic growth alone.